This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Hyperuricemia/ gout	ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1)	<i>In vitro</i> studies identified small molecule structural correctors of ABCG2 that could help treat gout. The Q141K mutation in ABCG2 decreases urate transport and has been associated with an increased risk of developing gout. SAR studies identified a small molecule that corrected the folding of the Q141K mutant ABCG2 and increased expression of the protein in cultured cells compared with vehicle. Next steps include screening for and developing additional Q141K corrector molecules to treat gout. SciBX 6(12); doi:10.1038/scibx.2013.290 Published online March 28, 2013	Patent application filed; available for licensing	Woodward, O.M. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online March 14, 2013; doi:10.1073/pnas.1214530110 Contact: William B. Guggino, The Johns Hopkins University School of Medicine, Baltimore, Md. e-mail: wguggino@jhmi.edu Contact: Owen M. Woodward, same affiliation as above e-mail: owenw@jhmi.edu or owenw1@gmail.com